Successful Immunotherapy Rechallenge Without Recurrence of Hemophagocytic Lymphohistiocytosis in a Patient With Metastatic Endometrial Cancer Previously Treated With Dostarlimab

Hemophagocytic lymphohistiocytosis (HLH) is a rare but potentially fatal immune hyperactivation syndrome that can be induced by immune checkpoint inhibitors (ICIs). We report a case of a 72-year-old woman with metastatic endometrial carcinoma who developed HLH after dostarlimab treatment and underwent successful immunotherapy rechallenge with pembrolizumab-lenvatinib plus prophylactic corticosteroids without HLH recurrence. Close biological monitoring ensured no relapse of HLH during rechallenge.